Novartis

Sanofi’s billion-dollar multiple sclerosis drug faces competitive threat from Novartis, J&J agents

On Friday, Novartis presented data at ECTRIMS showing that Arzerra had superior efficacy to Sanofi’s Aubagio. Johnson & Johnson’s Janssen division had presented data for its drug, ponesimod, two days...

Read more
STAT Plus: Reeling from scandal, Novartis vows to voluntarily release info on manipulated data in the future

Seeking to appease angry regulators, Novartis (NVS) committed to notifying the Food and Drug Administration within five business days of learning of any “credible allegation” in which manipulated data may...

Read more
STAT Plus: Pharmalittle: AstraZeneca stumbles in lung cancer; FDA official on Novartis data scandal says ‘we got lucky’

Rise and shine, everyone, the middle of the week is already here. Time flies when you’re having … fill in the blank here. Meanwhile, a hazy, muggy morning is unfolding...

Read more
Top scientist categorically denies any wrongdoing in Novartis data manipulation scandal

The Novartis scientist who was ousted by the drug maker in connection with a scandal over data manipulation broke his silence late Monday, saying through a lawyer that he categorically...

Read more
STAT Plus: Pharmalittle: Novartis exec sold stock before FDA announced data scandal; FDA OKs fewer new generics this year

Good morning, everyone, and welcome to another working week. We hope the weekend respite — or holiday break, for some — was invigorating and refreshing, because the oh-so-familiar routine of...

Read more
STAT Plus: Pharmalittle: New antibiotic approved for drug-resistant TB strain; Novartis dismissed top scientists over data scandal

Good morning, everyone, and how are you today? We are doing just fine, thank you, especially since the Pharmalot campus is unusually quiet. A short person is sleeping in and...

Read more
Memo to the Novartis CEO: When in doubt, give the FDA a heads-up

For someone who has made a point of trying to steer Novartis (NVS) away from scandal, Vas Narasimhan has committed a puzzling blunder. Last week, the Food and Drug Administration...

Read more
Listen: Novartis and the no good, very bad week

Why did Novartis keep its scandal to itself? Who knew what and when? And is there such thing as too much Peloton time? We discuss all that and more on...

Read more
Senators blast Novartis over data manipulation before approval of Zolgensma

WASHINGTON — A group of senators, including presidential hopefuls Sens. Elizabeth Warren (D-Mass.) and Bernie Sanders (I-Vt.), blasted Novartis on Friday for failing to promptly disclose that falsified data were...

Read more
STAT Plus: Pharmalittle: A new scandal for Novartis; opioid distributors offer to settle lawsuits

Good morning. Elizabeth Cooney here again in Boston, filling in for Ed Silverman while he takes a summer break. As he would no doubt remind us, we’ve made it to...

Read more
Novartis CEO: ‘We tried to do the right things’ in FDA data scandal

Novartis CEO Vas Narasimhan on Wednesday defended his company’s decision to wait three months to tell authorities about falsified data submitted to the Food and Drug Administration, saying the company...

Read more
Novartis was aware of manipulation of data supporting gene therapy approval, FDA says

AveXis, the gene therapy subsidiary of Swiss pharma giant Novartis, was aware of “data manipulation” involving its Zolgensma gene therapy for spinal muscular atrophy before it was approved in May,...

Read more
STAT Plus: Novartis sets aside $700 million to settle long-running bribery allegations in the U.S.

Novartis (NVS) has set aside $700 million to settle a long-running lawsuit in which the federal government alleged the drug maker used kickbacks to doctors — including fishing trips, lavish...

Read more
STAT Plus: Some insurers are pushing back on the high price for a Novartis gene therapy

Barely a month after Novartis (NVS) won U.S. regulatory approval for its gene therapy — the most expensive in the world — nearly a dozen insurers are taking steps to...

Read more
Asia-Pacific Over the Counter (OTC) Drugs Market Report 2019-2024 with Key Player Profiles on Johnson & Johnson, Novartis, Bayer, GlaxoSmithKline, and Pfizer – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific over the Counter (OTC) Drugs Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. The growth propelling factors of the...

Read more
STAT Plus: ICER says pricing for Novartis MS drug ‘far out of line,’ but more groups push back

A controversial cost-effectiveness watchdog has declared that Novartis (NVS) priced its recently approved multiple sclerosis drug “far out of line,” the latest slap at the pharmaceutical industry over pricing for...

Read more
STAT Plus: Pharmalittle: FDA plans ‘concierge service’ for expanded access to cancer meds; Novartis ‘anchored’ gene therapy price

Top of the morning to you, and a fine one it is. A shiny sun and crisp breeze are enveloping the Pharmalot campus, where the short people have left for...

Read more
STAT Plus: Novartis hopes new survival data will help its Kisqali take on Pfizer’s Ibrance. It probably won’t

A pretty impressive result from ASCO that’s also being published in the New England Journal of Medicine: Kisqali, a breast cancer drug from Novartis (NVS), dramatically extended survival in younger...

Read more
STAT Plus: Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy

CAMBRIDGE, Mass. — Days before his company is expected to win approval of the most expensive drug ever, the head of Swiss drug giant Novartis said Wednesday he could justify...

Read more
At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug

The Food and Drug Administration on Friday approved the first gene therapy for a type of spinal muscular atrophy, a lifesaving treatment for infants that will also be the most...

Read more